Adenoviral delivery of vegf promotes short term angiogenic effect

Matthew J. Gounis, Baruch B. Lieber, Keith A. Webster, M. Grazia Spiga, Nanette H. Bishopric, Ajay K. Wakhloo

Research output: Chapter in Book/Report/Conference proceedingConference contribution


A longitudinal in vivo study has been completed to evaluate the angiogenic benefit of an adenoviral vector used to express vascular endothelial growth factor (VEGF 165). Subsequently, numerous methods of therapeutic angiogenesis, including different gene delivery vehicles as well as the route of administration of these vectors, have been studied using angiographic time-intensity data. Mathematical modeling of these data provides indices of the formation and function of new vessel growth in response to the treatment modality. The angiographic and immunohistological results demonstrate that adenoviral (Ad) delivery of VEGF promotes a rapid angiogenic effect within the first week of treatment. However, this effect is not sustained and returns to control levels within three weeks. These results support the conclusion that Ad mediated therapeutic angiogenesis may not provide long term benefit.

Original languageEnglish (US)
Title of host publicationProceedings of the 2005 Summer Bioengineering Conference, 2005 SBC
Number of pages2
StatePublished - Dec 1 2005
Event2005 Summer Bioengineering Conference - Vail, CO, United States
Duration: Jun 22 2005Jun 26 2005

Publication series

NameProceedings of the 2005 Summer Bioengineering Conference


Other2005 Summer Bioengineering Conference
Country/TerritoryUnited States
CityVail, CO

ASJC Scopus subject areas

  • Engineering(all)


Dive into the research topics of 'Adenoviral delivery of vegf promotes short term angiogenic effect'. Together they form a unique fingerprint.

Cite this